FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model

BACKGROUND: Malignant mesothelioma (MM) is a very aggressive type of cancer, with a dismal prognosis and inherent resistance to chemotherapeutics. Development and evaluation of new therapeutic approaches is highly needed. Immunosuppressant FTY720, approved for multiple sclerosis treatment, has recen...

Descripción completa

Detalles Bibliográficos
Autores principales: Szymiczek, Agata, Pastorino, Sandra, Larson, David, Tanji, Mika, Pellegrini, Laura, Xue, Jiaming, Li, Shuangjing, Giorgi, Carlotta, Pinton, Paolo, Takinishi, Yasutaka, Pass, Harvey I., Furuya, Hideki, Gaudino, Giovanni, Napolitano, Andrea, Carbone, Michele, Yang, Haining
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5353897/
https://www.ncbi.nlm.nih.gov/pubmed/28298211
http://dx.doi.org/10.1186/s12967-017-1158-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5353897/
https://www.ncbi.nlm.nih.gov/pubmed/28298211
http://dx.doi.org/10.1186/s12967-017-1158-z

Ejemplares similares